COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder London, UK – 3 November 2021             COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...